Clinic
Chemawa Indian Health Center DHHS Ihs Western Oregon Serv Unit
Chemawa Indian Health Center DHHS Ihs Western Oregon Serv Unit was paid $15.83M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 90853, Group psychotherapy (other than of a multiple-family group) — 38% of everything it billed.
33Billing provider infoCHEMAWA INDIAN HEALTH CENTER DHHS IHS WESTERN OREGON SERV UNIT
SALEM, OR 97305
SALEM, OR 97305
33aNPI1578565347assigned 08/11/2005
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$15.83M
24GClaims50,522
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Oregon
Rank by total paid#6 of 40
Median peer was paid$517K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,537 | $4.06M | |
| 2019 | 9,139 | $2.64M | |
| 2020 | 3,306 | $1.60M | |
| 2021 | 4,105 | $1.45M | |
| 2022 | 10,512 | $2.96M | |
| 2023 | 5,602 | $1.73M | |
| 2024incomplete | 3,321 | $1.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90853 | Group psychotherapy (other than of a multiple-family group) | 38% | 13,637 | 2,235 | $6.09M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 17% | 4,702 | 2,498 | $2.65M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 3,344 | 3,040 | $1.74M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 7.6% | 2,745 | 1,846 | $1.21M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.4% | 1,253 | 1,112 | $535K |
| D0191 | 3.2% | 1,002 | 988 | $505K | |
| 99411 | 3.0% | 1,359 | 1,042 | $478K | |
| D1110 | Prophylaxis - adult | 1.7% | 659 | 656 | $265K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.6% | 481 | 471 | $256K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.4% | 511 | 471 | $229K |
| 0012A | 1.4% | 251 | 242 | $215K | |
| 0011A | 1.2% | 263 | 242 | $192K |
63 more codes
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 1.2% | 410 | $184K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.1% | 282 | $170K |
| D0150 | Comprehensive oral evaluation - new or established patient | 1.1% | 333 | $167K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 298 | $111K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 225 | $107K |
| 96160 | <1% | 316 | $106K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,507 | $90K |
| D0140 | Limited oral evaluation - problem focused | <1% | 144 | $63K |
| 92002 | <1% | 129 | $49K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 116 | $41K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 142 | $38K |
| D2150 | Silver amalgam - two surfaces, primary or permanent | <1% | 110 | $24K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,067 | $23K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,069 | $23K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 38 | $22K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 215 | $21K |
| D0120 | Dental checkup, returning patient | <1% | 50 | $21K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,919 | $19K |
| H0032 | Mental health service plan development by non-physician | <1% | 45 | $17K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 55 | $17K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 919 | $13K |
| 0064A | <1% | 30 | $13K | |
| D0274 | Bitewings - four radiographic images | <1% | 912 | $12K |
| 0004A | <1% | 16 | $10K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 37 | $10K |
| 0001A | <1% | 41 | $10K | |
| D0330 | Panoramic radiographic image | <1% | 398 | $8K |
| 0072A | <1% | 14 | $7K | |
| 0071A | <1% | 16 | $7K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,192 | $7K |
| 80061 | Lipid panel | <1% | 827 | $7K |
| H2032 | Activity therapy, per 15 minutes | <1% | 40 | $6K |
| 97802 | <1% | 17 | $6K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 12 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 102 | $5K |
| 0124A | <1% | 21 | $4K | |
| 81025 | <1% | 874 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 628 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 75 | $3K |
| D2140 | <1% | 17 | $3K | |
| 80053 | Comprehensive metabolic panel | <1% | 426 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 433 | $828.79 |
| 90686 | <1% | 1,006 | $655.76 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 97 | $653.54 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 269 | $652.50 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 87 | $293.67 |
| D1206 | Topical application of fluoride varnish | <1% | 209 | $241.10 |
| 82728 | <1% | 59 | $181.26 | |
| 80076 | <1% | 18 | $127.08 | |
| 92552 | <1% | 819 | $68.43 | |
| 83550 | <1% | 47 | $55.08 | |
| 92134 | <1% | 13 | $36.53 | |
| 83540 | <1% | 47 | $36.24 | |
| 86592 | 0% | 415 | $0.00 | |
| 90651 | 0% | 46 | $0.00 | |
| 92551 | 0% | 285 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 28 | $0.00 |
| 94010 | 0% | 15 | $0.00 | |
| 90656 | 0% | 30 | $0.00 | |
| 90620 | 0% | 55 | $0.00 | |
| 90863 | 0% | 60 | $0.00 | |
| H2027 | Psychoeducational service, per 15 minutes | 0% | 101 | $0.00 |
| 90734 | 0% | 92 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHERBISON, LAURA (ACTING CHIEF EXECUTIVE OFFICER)